RT Journal Article
SR Electronic
T1 Core Outcome Set for Clinical Trials of COVID-19 based on Traditional Chinese and Western Medicine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.23.20041533
DO 10.1101/2020.03.23.20041533
A1 Qiu, Ruijin
A1 Zhao, Chen
A1 Liang, Tengxiao
A1 Hao, Xuezeng
A1 Huang, Ya
A1 Zhang, Xiaoyu
A1 Chen, Zhao
A1 Wei, Xuxu
A1 Zhao, Mengzhu
A1 Zhong, Changming
A1 Hu, Jiayuan
A1 Li, Min
A1 Han, Songjie
A1 He, Tianmai
A1 Chen, Jing
A1 Shang, Hongcai
YR 2020
UL http://medrxiv.org/content/early/2020/04/07/2020.03.23.20041533.abstract
AB Background Development of a core outcome set (COS) for clinical trials for COVID-19 is urgent because of the pandemic wreaking havoc worldwide and the heterogeneity of outcomes in clinical trials.Methods A preliminary list of outcomes were developed after a systematic review of protocols of clinical trials for COVID-19. Then, two rounds of the Delphi survey were conducted. Stakeholders were traditional Chinese medicine (TCM) experts, Western medicine (WM) experts, nurses and the public. Patients with confirmed COVID-19 were also invited to participate in a questionnaire written in understandable language. Frontline clinicians, as well as nurse, methodologist, evidence based-medicine researcher, and staff from the Chinese Clinical Trials Registry participated by video conference to vote.Results Ninety-seven eligible study protocols were identified from 160 clinical trials. Seventy-six outcomes were identified from TCM clinical trials and 126 outcomes were identified from WM clinical trials. Finally, 145 outcomes were included in the first round of the Delphi survey. Then, a COS for clinical trials of TCM and WM was developed. The COS include clinical outcomes (recovery/improvement/progression/death), etiology (SARS-CoV-2 nucleic-acid tests, viral load), inflammatory factor (C-reactive protein), vital signs (temperature, respiration), blood and lymphatic-system parameters (lymphocytes, virus antibody), respiratory outcomes (Pulmonary imaging, blood oxygen saturation, PaO2/FiO2 ratio, arterial blood gas analysis, mechanical ventilation, oxygen intake, pneumonia severity index), clinical efficacy (prevalence of preventing patients with mild-to-moderate disease progressing to severe disease), symptoms (clinical symptom score). Outcomes were recommended according to different types of disease. Outcome measurement instrument/definition were also recommended.Conclusion A COS for COVID-19 may improve consistency of outcome reporting in clinical trials.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialhttp://www.comet-initiative.org/Studies/Details/1507Clinical Protocols http://www.comet-initiative.org/Studies/Details/1507 Funding StatementThis work was supported by the National High-level Personnel of Special Support Program (W02020052).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data is from public database and does not include identifiable patient data.